BTK and mantle cell lymphoma: In addition, avitinib also acts as a novel Bruton’s tyrosine kinase (BTK) inhibitor, which inhibits the phosphorylation of BTK and the PI3K/Akt signalling pathway in mononuclear cell leukaemia (MCL) cells [20].